A year ago, the impact of COVID-19 vaccines was at the forefront of everybody’s minds. Our base case was that they would be effective, become widely available and allow the economy to recover, which proved largely accurate. However, COVID-19 very much remains with us, as the emergence of the new Omicron variant has reminded us.
Pour lire cet article, vous avez besoin d'un abonnement à Investment Officer. Si vous n'avez pas encore d'abonnement, cliquez sur 'Abonner' pour connaître les différentes formules d'abonnement.
